• Organizations: Alkeus Pharmaceuticals
Favorable safety data supports Alkeus' oral gildeuretinol for dry AMD
Pipeline

Favorable safety data supports Alkeus' oral gildeuretinol for dry AMD

Presented during ARVO 2025, the modified form of Vitamin A demonstrated a slower decline in vision-related quality of life among patients diagnosed with GA secondary to AMD.
Alkeus receives two rare disease FDA designations for Stargardt candidate
Pipeline

Alkeus receives two rare disease FDA designations for Stargardt candidate

New statuses join gildeuretinol’s (ALK-001) previous Fast Track and Orphan Drug designations; gives company potential eligibility for priority review voucher.
Despite missing primary outcomes, Alkeus' phase 3 GA trial shows promise
Pipeline

Despite missing primary outcomes, Alkeus' phase 3 GA trial shows promise

Oral gildeuretinol's clinically meaningful reduction in GA lesion growth warrants further clinical development, company says.
Alkeus releases positive data from ongoing phase 3 Stargardt trial
Pipeline

Alkeus releases positive data from ongoing phase 3 Stargardt trial

TEASE-3 study is evaluating gildeuretinol acetate for treating early stage of disease in teenagers.